Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer

OBJECTIVE: To assess the efficacy and toxicity of cediranib, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with docetaxel-based therapy. PATIENTS AND METHODS: The s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dahut, William L., Madan, Ravi A., Karakunnel, Joyson J., Adelberg, David, Gulley, James L., Turkbey, Ismail B., Chau, Cindy H., Spencer, Shawn D., Mulquin, Marcia, Wright, John, Parnes, Howard L., Steinberg, Seth M., Choyke, Peter L., Figg, William D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3660464/
https://ncbi.nlm.nih.gov/pubmed/23419134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1464-410X.2012.11667.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados